AP NEWS
Click to copy
Press release content from Business Wire. The AP news staff was not involved in its creation.
Click to copy
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Severe Psoriasis - Pipeline Insight, 2019 - ResearchAndMarkets.com

April 1, 2019

DUBLIN--(BUSINESS WIRE)--Apr 1, 2019--The “Severe Psoriasis - Pipeline Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

The report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Severe Psoriasis development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Scope of the Report

Reasons to Buy

Key Topics Covered

1. Report Introduction

2. Severe Psoriasis Overview

3. Pipeline Therapeutics

4. Comparative Analysis

5. Products in Clinical Stage

6. Products in Pre-Clinical and Discovery Stage

7. Therapeutic Assessment

8. Inactive Products

Companies Mentioned

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/thgcvp/severe_psoriasis?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190401005807/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Immune Disorders Drugs,Psoriasis Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 04/01/2019 03:01 PM/DISC: 04/01/2019 03:01 PM

http://www.businesswire.com/news/home/20190401005807/en

All contents © copyright 2019 The Associated Press. All rights reserved.